Calcineurin inhibitor-induced and Ras-mediated overexpression of VEGF in renal cancer cells involves mtor through the regulation of PRAS40

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Basu, Aninda ^a,b   Banerjee, Pallavi ^a,b   Contreras, Alan G ^a,b   Flynn, Evelyn ^a,b   Pal, Soumitro ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN; PRAS 40 PROTEIN; PROLINE RICH PROTEIN; PROTEIN KINASE C DELTA; PROTEIN KINASE C ZETA; RAS PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; AKT1S1 PROTEIN, HUMAN; CALCINEURIN; MTOR PROTEIN, HUMAN; RAPAMYCIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TARGET OF RAPAMYCIN KINASE; VASCULOTROPIN A;

ARTICLE; CANCER CELL; CANCER GROWTH; CARCINOGENESIS; COMPLEX FORMATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VIVO STUDY; KIDNEY CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; DRUG ANTAGONISM; GENETIC TRANSCRIPTION; GENETICS; KIDNEY TUMOR; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

MAMMALIA; RAPTORES;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CALCINEURIN; CELL LINE, TUMOR; HUMANS; KIDNEY NEOPLASMS; PHOSPHORYLATION; RAS PROTEINS; SIROLIMUS; TOR SERINE-THREONINE KINASES; TRANSCRIPTION, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80052004396     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023919     Document Type: Article

References (50)

1. Peddi VR, First MR, (2001) Recent advances in immunosuppressive therapy for renal transplantation. Semin Dial 14: 218-222.
2. Durrbach A, Francois H, Beaudreuil S, Jacquet A, Charpentier B, (2010) Advances in immunosuppression for renal transplantation. Nat Rev Nephrol 6: 160-167.
3. Campistol JM, (2010) Minimizing the risk of cancer in transplant patients. G Ital Nefrol 27 (Suppl 50): S81-85.
4. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C, (2004) Cancer after kidney transplantation in the United States. Am J Transplant 4: 905-913.
5. Bustami RT, Ojo AO, Wolfe RA, Merion RM, Bennett WM, et al. (2004) Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant 4: 87-93.
6. Wimmer CD, Rentsch M, Crispin A, Illner WD, Arbogast H, et al. (2007) The janus face of immunosuppression- de novo malignancy after renal transplantation: the experience of the Transplantation Center Munich. Kidney Int 71: 1271-1278.
7. Campistol JM, (2009) Minimizing the risk of posttransplant malignancy. Transplantation 87: S19-22.
8. Jamil B, Nicholls K, Becker GJ, Walker RG, (1999) Impact of acute rejection therapy on infections and malignancies in renal transplant recipients. Transplantation 68: 1597-1603.
9. Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, et al. (1999) Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 397: 530-534.
10. Guba M, Graeb C, Jauch KW, Geissler EK, (2004) Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation 77: 1777-1782.
11. Morath C, Mueller M, Goldschmidt H, Schwenger V, Opelz G, et al. (2004) Malignancy in renal transplantation. J Am Soc Nephrol 15: 1582-1588.
12. Webster AC, Craig JC, Simpson JM, Jones MP, Chapman JR, (2007) Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: a cohort study of 15,183 recipients. Am J Transplant 7: 2140-2151.
13. Klee CB, Crouch TH, Krinks MH, (1979) Calcineurin: a calcium- and calmodulin-binding protein of the nervous system. Proc Natl Acad Sci U S A 76: 6270-6273.
14. Graef IA, Chen F, Chen L, Kuo A, Crabtree GR, (2001) Signals transduced by Ca(2+)/calcineurin and NFATc3/c4 pattern the developing vasculature. Cell 105: 863-875.
15. Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, et al. (1991) Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 66: 807-815.
16. Pan F, Sun L, Kardian DB, Whartenby KA, Pardoll DM, et al. (2007) Feedback inhibition of calcineurin and Ras by a dual inhibitory protein Carabin. Nature 445: 433-436.
17. Cho CS, Elkahwaji J, Chang Z, Scheunemann TL, Manthei ER, et al. (2003) Modulation of the electrophoretic mobility of the linker for activation of T cells (LAT) by the calcineurin inhibitors CsA and FK506: LAT is a potential substrate for PKC and calcineurin signaling pathways. Cell Signal 15: 85-93.
18. Koehl GE, Andrassy J, Guba M, Richter S, Kroemer A, et al. (2004) Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation 77: 1319-1326.
19. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, et al. (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8: 128-135.
20. Dvorak HF, Brown LF, Detmar M, Dvorak AM, (1995) Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146: 1029-1039.
21. Folkman J, (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31.
22. Basu A, Contreras AG, Datta D, Flynn E, Zeng L, et al. (2008) Overexpression of vascular endothelial growth factor and the development of post-transplantation cancer. Cancer Res 68: 5689-5698.
23. Basu A, Datta D, Zurakowski D, Pal S, (2010) Altered VEGF mRNA stability following treatments with immunosuppressive agents: implications for cancer development. J Biol Chem 285: 25196-25202.
24. Datta D, Contreras AG, Basu A, Dormond O, Flynn E, et al. (2009) Calcineurin inhibitors activate the proto-oncogene Ras and promote protumorigenic signals in renal cancer cells. Cancer Res 69: 8902-8909.
25. Pal S, Datta K, Khosravi-Far R, Mukhopadhyay D, (2001) Role of protein kinase Czeta in Ras-mediated transcriptional activation of vascular permeability factor/vascular endothelial growth factor expression. J Biol Chem 276: 2395-2403.
26. Dantal J, Soulillou JP, (2005) Immunosuppressive drugs and the risk of cancer after organ transplantation. N Engl J Med 352: 1371-1373.
27. Monaco AP, (2009) The role of mTOR inhibitors in the management of posttransplant malignancy. Transplantation 87: 157-163.
28. Geissler EK, Schlitt HJ, (2010) The potential benefits of rapamycin on renal function, tolerance, fibrosis, and malignancy following transplantation. Kidney Int 78: 1075-1079.
29. Han W, Ming M, He TC, He YY, (2010) Immunosuppressive cyclosporin A activates AKT in keratinocytes through PTEN suppression: implications in skin carcinogenesis. J Biol Chem 285: 11369-11377.
30. Leseux L, Laurent G, Laurent C, Rigo M, Blanc A, et al. (2008) PKC zeta mTOR pathway: a new target for rituximab therapy in follicular lymphoma. Blood 111: 285-291.
31. Minhajuddin M, Bijli KM, Fazal F, Sassano A, Nakayama KI, et al. (2009) Protein kinase C-delta and phosphatidylinositol 3-kinase/Akt activate mammalian target of rapamycin to modulate NF-kappaB activation and intercellular adhesion molecule-1 (ICAM-1) expression in endothelial cells. J Biol Chem 284: 4052-4061.
32. Moschella PC, Rao VU, McDermott PJ, Kuppuswamy D, (2007) Regulation of mTOR and S6K1 activation by the nPKC isoforms, PKCepsilon and PKCdelta, in adult cardiac muscle cells. J Mol Cell Cardiol 43: 754-766.
33. Kumar V, Pandey P, Sabatini D, Kumar M, Majumder PK, et al. (2000) Functional interaction between RAFT1/FRAP/mTOR and protein kinase cdelta in the regulation of cap-dependent initiation of translation. EMBO J 19: 1087-1097.
34. Garcia JA, Danielpour D, (2008) Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. Mol Cancer Ther 7: 1347-1354.
35. Wullschleger S, Loewith R, Hall MN, (2006) TOR signaling in growth and metabolism. Cell 124: 471-484.
36. Tee AR, Blenis J, (2005) mTOR, translational control and human disease. Semin Cell Dev Biol 16: 29-37.
37. Bjornsti MA, Houghton PJ, (2004) The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4: 335-348.
38. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, et al. (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: 2271-2281.
39. Sarbassov DD, Ali SM, Sabatini DM, (2005) Growing roles for the mTOR pathway. Curr Opin Cell Biol 17: 596-603.
40. Sancak Y, Thoreen CC, Peterson TR, Lindquist RA, Kang SA, et al. (2007) PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell 25: 903-915.
41. Vander Haar E, Lee SI, Bandhakavi S, Griffin TJ, Kim DH, (2007) Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol 9: 316-323.
42. Wang L, Harris TE, Roth RA, Lawrence JC Jr, (2007) PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding. J Biol Chem 282: 20036-20044.
43. Oshiro N, Takahashi R, Yoshino K, Tanimura K, Nakashima A, et al. (2007) The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1. J Biol Chem 282: 20329-20339.
44. Carriere A, Romeo Y, Acosta-Jaquez HA, Moreau J, Bonneil E, et al. (2011) ERK1/2 phosphorylate Raptor to promote Ras-dependent activation of mTOR complex 1 (mTORC1). J Biol Chem 286: 567-577.
45. Chen C, Johnston TD, Jeon H, Gedaly R, McHugh P, et al. (2009) Cyclosporin A up-regulates and activates protein kinase C-zeta in EBV-infected and EBV-transformed human B-cells. J Surg Res 153: 156-161.
46. Mireuta M, Darnel A, Pollak M, (2010) IGFBP-2 expression in MCF-7 cells is regulated by the PI3K/AKT/mTOR pathway through Sp1-induced increase in transcription. Growth Factors 28: 243-255.
47. Harada H, Itasaka S, Kizaka-Kondoh S, Shibuya K, Morinibu A, et al. (2009) The Akt/mTOR pathway assures the synthesis of HIF-1alpha protein in a glucose- and reoxygenation-dependent manner in irradiated tumors. J Biol Chem 284: 5332-5342.
48. Mukhopadhyay D, Knebelmann B, Cohen HT, Ananth S, Sukhatme VP, (1997) The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol Cell Biol 17: 5629-5639.
49. Khosravi-Far R, White MA, Westwick JK, Solski PA, Chrzanowska-Wodnicka M, et al. (1996) Oncogenic Ras activation of Raf/mitogen-activated protein kinase-independent pathways is sufficient to cause tumorigenic transformation. Mol Cell Biol 16: 3923-3933.
50. Khosravi-Far R, Chrzanowska-Wodnicka M, Solski PA, Eva A, Burridge K, et al. (1994) Dbl and Vav mediate transformation via mitogen-activated protein kinase pathways that are distinct from those activated by oncogenic Ras. Mol Cell Biol 14: 6848-6857.